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Background: Carbapenem-resistant Gram-negative bacteria
(CR GNB) are subject of public health concerns and may be associ-
atedwithworse outcomes. In this studyweaimed to assess 28-days
survival of patientswith bacteraemia due toGramnegative species.
Methods & Materials: Cross-sectional multicentre study was
performed in patients with drug-resistant Gram-negative bacter-
aemia in Slovakia in November 2011- January 2012. Antibiotic
susceptibility testing was performed according to the European
Committee on Antimicrobial Susceptibility Testing. Kaplan-Meier
curves were used to assess 28-days survival and were analysed
with Log rank test to compare survival of patientswith andwithout
infection caused by CR GNB.
Results: Altogether, 257 cases with drug-resistant GNB bac-
teraemia were identiﬁed (59,4% males; median age 62 years, IQR
50-75), of them 45 (17,5%)were due to CR GNB. Twenty-eight-days
mortality, was signiﬁcantly higher in group of CR GNB cases (42,2%
vs. 25,5%, p=0,029), while in overall mortality there was no sta-
tistically signiﬁcant difference (64,4% vs. 49,06%, p=0,086). Median
time from positive blood culture to death was 9,5 days in CR GNB
group, and 34,5 days in carbapenem-susceptible group (p=0,042).
Also, signiﬁcant difference in28-days survivalwasnoticed compar-
ing patients with carbapenem susceptible and CR GNB infection
(Log rank test p=0,033). Regarding the risk factors, polymicrobial
infection (p=0,019), hospitalization in intensive care unit (p<0,001)
andhospitalizationduring thewinter and/or spring (p=0,054),were
associated with CR infection.
Conclusion: In this study, carbapenem-resistance in GNB
species causing bloodstream infection was associated with signif-
icantly worse outcome and decreased probability of survival. This
is underscoring importance of careful control strategies to avoid
spread of CR GNB among patients.
(This study was partially supported with Trnava University Grant,
No 7/TU/12).
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Background:Pyrazinamide (PZA)has theunique ability to erad-
icate semi-dormant bacilli in acidic environments not targeted by
other drugs. Addition of pyrazinamide (PZA) has enabled shorten-
ing of the duration of tuberculosis (TB) treatment regimens. PZA is
likely to continue to play a role in novel TB treatment regimens but
little information is available on the prevalence of PZA resistance
as PZA drug susceptibility testing (DST) is not performed routinely
due to technical difﬁculties. Studies have suggested an association
between mutations in the pncA gene and in vitro PZA resistance.
Objectives: We aimed to determine the association between
mutations in the pncA gene and phenotypic resistance to PZA in
clinical isolates from patients with rifampicin resistant TB.
Methods & Materials: A total of 233 Mycobacterium tuberculo-
sis isolates identiﬁed as rifampicin (RIF) resistant by the National
Health Laboratory service (routine DST/Xpert MTB/RIF) from three
provinces in SouthAfricawere subjected to culture-based PZAdrug
susceptibility testing using BD BACTEC MGIT 960 PZA Mycobacte-
rial Detection System and targeted DNA sequencing of the pncA
gene. Isolates were the initial clinical isolates collected prior to
initation of tuberculosis treatment.
Results: Based on phenotypic testing, 117 (50%) of the RIF
resistant isolates were also resistant to PZA at a concentration
of 100g/ml. DNA sequencing identiﬁed polymorphisms (sin-
gle nucleotides polymorphisms/insertion/deletion) in 109 (93%)
of the phenotypically PZA resistant isolates. All 109 were non-
synonymous/insertions/deletions. Eight of the phenotypically PZA
susceptible isolates hadmutations in thepncA geneofwhich6were
non-synomymous and 3 were synonymous. A total of 39 different
polymorphisms in the pncA gene were identiﬁed, with the insert at
codon 173 (G) being most prevalent. Using phenotypic PZA resis-
tance as the gold standard, sensitivity and speciﬁcity of genetic
detection of PZA resistance was 93.2% and 95.7%, respectively.
Conclusion: The observed strong association between geno-
typic and phenotypic PZA resistance in clinical RIF resistant isolates
suggests that bothmethods couldbeused fordetectionof PZA resis-
tance. Thehigh (50%)proportionofRIF resistant isolatesharbouring
PZA resistancehighlights theneed for routine PZADST and cautions
against the inclusion of PZA in multi-drug resistant TB treatment
regimens.
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